Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

Heart disease is one of the leading causes of death worldwide, and while lifestyle choices like diet, exercise, and smoking ...

The company has launched a competition to offer grants of up to $100,000 to multiple projects that can uncover "new insights about the role of the PCSK9 protein/gene in health and disease", with a ...

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

PCSK9 Program Enrollment Ongoing in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 VERVE-102 is a novel, investigational gene editing medicine designed to be a single course treatment that ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

VERVE-102 is a novel, investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving low ...

The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the ...